Fosun Pharmaceutical is a listed company which started A shareinitial public offering in 1998 and H share in 2012. The English name of the company was initially known as Shanghai Fortune Industrial Joint-Stock Co., Ltd., but the transliteration of 复星 was later changed from Fortune to Fosun, as well as changing the name from Industrial to Pharmaceutical. The company also shorten the transliteration of the legal suffix 股份有限公司 from Joint-Stock Co., Ltd. to just Co., Ltd.. Shanghai Fortune Industrial Joint-Stock Co., Ltd. was incorporated in 1998, but its predecessor, Shanghai Fortune Industrial Company was incorporated in January 1994. The majority shareholders in December 1994 were Fosun High Technology and its parent company Guangxin Technology ; Guangxin Technology was owned by Guo Guangchang, Liang Xinjun, Wang Qunbin and Fan Wei. In 2003 Fosun Pharmaceutical acquired 49% stake of Sinopharm Group. In 2008, a year before the initial public offering of Sinopharm Group, Fosun Pharmaceutical owned the direct parent company of Sinopharm Group, Sinopharm Industrial Investment instead; the majority owner of the joint venture was state-owned China National Pharmaceutical Group. An intermediate parent company of Fosun Pharma, Fosun International, became a listed company in 2007. In 2014 Fosun Pharma was part of a consortium to acquire US-listed Chindex International, which owned private hospitals in mainland China. In 2016, according to the Financial Times, Fosun Pharmaceutical made the largest Indian corporate takeover by a Chinese company, by acquiring Gland Pharma for no more than US$1.26 billion. Despite the offer was revised in 2017 to seek approval from Indian regulators. In October 2017, the acquisition of 74% stake of Gland Pharma was completed. In September 2017, Israeli subsidiary Sisram Medical was spin-off as a separate listed company on the Stock Exchange of Hong Kong., Fosun Pharma owned Sisram Medical 52.83% shares. In October 2017 Fosun Pharmaceutical, via subsidiaries Fosun Pharmaceutical A.G. and Fosun Industrial bought Tridem Pharma, according to the Financial Times, "an Africa-focused French drug distributor", for not more than €63 million.
Shareholders
Fosun Pharmaceutical had two classes of ordinary share: A shares which only traded in mainland China as well as H share which only traded in Hong Kong. , there was 2,011,190,000 number of A shares and 483,941,000 number of H shares, for a total of 2,495,131,000, which Fosun International's wholly owned subsidiary, Fosun High Technology, owned 936,575,490 and 9,989,000 number of shares respectively. Fosun High Technology also once owned 23.45% of the convertible bond of Fosun Pharma in 2003. , co-founder of Fosun High Technology and now co-owner of the parent company of Fosun International, Guo Guangchang and Wang Qunbin, still served as non-executive directors of Fosun Pharmaceutical. , the market capitalization of the H share of Fosun Pharma was HK$12,943,004,725.
